3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
13
Triple Negative Breast Neoplasms
7
Prostatic Neoplasms
7
Neoplasms
6
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Endometrial Neoplasms
2
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Premenopausal HR+/HER2- Metastatic Breast Cancer
1
Pheochromocytoma
1
Pathologic Complete Response
1
Paraganglioma
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Hemangiosarcoma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Extensive Stage Lung Small Cell Carcinoma
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Temozolomide
69
Bevacizumab
40
Radiotherapy
22
Magnetic Resonance Spectroscopy
20
Irinotecan
17
Specimen Handling
10
Carboplatin
10
Carmustine
9
X-Rays
7
Radiation
7
olaparib
6
Surgical Procedures, Operative
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Nivolumab
6
Everolimus
6
Cyclophosphamide
6
Biopsy
6
trametinib
5
Thalidomide
5
Cisplatin
5
pembrolizumab
4
palbociclib
4
fluorodopa F 18
4
erdafitinib
4
dabrafenib
4
Lomustine
4
Etoposide
4
Drug Therapy
4
Doxorubicin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Glioma
×
talazoparib
×
Clear all
NCT04740190
2025-06-11
TAC-GReD
The University of Hong Kong
Phase 2
Completed
33 enrolled